{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:49:23Z","timestamp":1775152163706,"version":"3.50.1"},"reference-count":32,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1185\/03007995.2014.928275","type":"journal-article","created":{"date-parts":[[2014,5,27]],"date-time":"2014-05-27T12:37:18Z","timestamp":1401194238000},"page":"2069-2083","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":23,"title":["Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study"],"prefix":"10.1185","volume":"30","clinical-trial-number":[{"clinical-trial-number":"nct01271933","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lesley M.","family":"Arnold","sequence":"first","affiliation":[{"name":"University of Cincinnati College of Medicine","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Arsenault","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Sherbrooke","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Huffman","sequence":"additional","affiliation":[{"name":"Meridien Research","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey L.","family":"Patrick","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Messig","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marci L.","family":"Chew","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Sanin","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Scavone","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Pauer","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew G.","family":"Clair","sequence":"additional","affiliation":[{"name":"Pfizer Inc","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,6,27]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20140"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23176"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.12.003"},{"issue":"10","key":"e_1_3_3_5_1","first-page":"S55","article-title":"A population-based survey and physician assessment of the characteristics and prevalence of fibromyalgia","volume":"65","author":"Adams E","year":"2013","unstructured":"Adams E, Daniel S, Chandran A, et al. A population-based survey and physician assessment of the characteristics and prevalence of fibromyalgia. Arthritis Rheum 2013;65(10 Suppl):S55","journal-title":"Arthritis Rheum"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2012.02.010"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2011.0206"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.09.008"},{"key":"e_1_3_3_9_1","first-page":"502","article-title":"A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia","volume":"35","author":"Mease PJ","year":"2008","unstructured":"Mease PJ, Russell IJ, Arnold LM, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-14","journal-title":"J Rheumatol"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.03.013"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110569"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20983"},{"key":"e_1_3_3_13_1","unstructured":"Lyrica (pregabalin) capsules [prescribing information] 2012. Available at: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=561 [Last accessed 27 December 2013]"},{"key":"e_1_3_3_14_1","unstructured":"World Health Organization. Adherence to long-term therapies \u2013 evidence for action 2003. Available at: http:\/\/apps.who.int\/medicinedocs\/en\/d\/Js4883e\/6.1.html [Last accessed 7 January 2014]"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S44646"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2012.18.7.527"},{"key":"e_1_3_3_17_1","unstructured":"New England Healthcare Institute. Thinking outside the pillbox: a system-wide approach to improving patient medication adherence for chronic disease 2009. Available at: http:\/\/www.nehi.net\/writable\/publication_files\/file\/pa_issue_brief_final.pdf [Last accessed 19 May 2014]"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2013.01.602"},{"key":"e_1_3_3_19_1","doi-asserted-by":"crossref","unstructured":"Chew ML Plotka A Alvey CW et al. Pharmacokinetics of pregabalin controlled-release in healthy volunteers: Effect of food in five single-dose randomized clinical pharmacology studies. Clin Drug Investig 2014 DOI 10.1007\/s40261-014-0211-4. [epub ahead of print]","DOI":"10.1007\/s40261-014-0211-4"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330203"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20531"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1413-35552010005000015"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2010.01047.x"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.00069.x"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2008.02.027"},{"key":"e_1_3_3_28_1","doi-asserted-by":"crossref","unstructured":"Raskin P Huffman C Toth C et al. Pregabalin in patients with inadequately treated painful diabetic peripheral neuropathy: a randomized withdrawal trial. Clin J Pain 2014;30:379-90","DOI":"10.1097\/AJP.0b013e31829ea1a1"},{"key":"e_1_3_3_29_1","doi-asserted-by":"crossref","unstructured":"Nasser K Kivitz AJ Maricic MJ et al. Twice daily vs once nightly dosing of pregabalin for fibromyalgia: a double-blind randomized clinical trial of efficacy and safety. Arthritis Care Res (Hoboken) 2014;66:293-300","DOI":"10.1002\/acr.22111"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2008.01.014"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e3181b12dec"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2008.03.005"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.09.005"}],"updated-by":[{"DOI":"10.1080\/03007995.2017.1292446","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T00:00:00Z","timestamp":1486684800000}}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1185\/03007995.2014.928275","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:32:14Z","timestamp":1772760734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1185\/03007995.2014.928275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,27]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1185\/03007995.2014.928275"],"URL":"https:\/\/doi.org\/10.1185\/03007995.2014.928275","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-05-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-06-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}